- Home
- BBIO vs MTZ Comparison
BBIO vs MTZ Comparison
Compare BBIO & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | MTZ |
|---|---|---|
| Founded | 2015 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 15.9B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BBIO | MTZ |
|---|---|---|
| Price | $77.89 | $167.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 21 |
| Target Price | $106.85 | ★ $318.38 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.12 |
| EPS | N/A | ★ 4.32 |
| Revenue | $502,076,000.00 | ★ $14,299,171,000.00 |
| Revenue This Year | $118.43 | $27.78 |
| Revenue Next Year | $51.86 | $17.08 |
| P/E Ratio | ★ N/A | $45.71 |
| Revenue Growth | ★ 126.26 | 16.22 |
| 52 Week Low | $60.55 | $164.31 |
| 52 Week High | $93.42 | $441.43 |
Technical Indicators
Market Signals| Indicator | BBIO | MTZ |
|---|---|---|
| Relative Strength Index (RSI) | 65.69 | 50.45 |
| Support Level | $63.16 | $164.31 |
| Resistance Level | $75.91 | $233.21 |
| Average True Range (ATR) | 2.16 | 10.48 |
| MACD | 1.10 | 2.93 |
| Stochastic Oscillator | 76.06 | 86.31 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.